glp-1 studies Receptor Agonists as Treatments for Type 2 Diabetes Results of cardiovascular outcomes trials

However, discontinuation is common, and clinical trials have demonstrated significant weight regain following cessation

On TikTok, Reddit, and some telehealth websites, microdosing glucagon-like peptide-1 (GLP-1) receptor agonist medications is pitched as a gentler, more flexible way to use drugs such as the GLP-1 agonist semaglutide (Ozempic, Wegovy), the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound), and oral nonpeptide GLP-1 receptor agonist orforglipron (Foundayo)

The average proportion of GLP-1 claims that were rejected rose from 30% before Wegovys launch, to 41% after Mounjaro hit the market, reflecting a change in the underlying access profile of GLP-1s for patients

Chronic tissue has adapted to a damaged state, and reversing this takes time